Clinical Data

Yellow tape measure with a variety of weight loss medication on blue background
Biotech

Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial

Lilly is now headed toward regulators, angling to submit approval applications for the next-gen obesity asset by the end of 2025.
Gabrielle Masson Aug 7, 2025 6:30am
pivot change turnaround direction walk away

HMNC recalibrates precision depression push after phase 2b miss

Aug 5, 2025 10:38am
dart board miss failure

Vertex drops asset in acute pain after phase 2 fail

Aug 4, 2025 5:34pm
White arrow on a road pointing to the rising sun

Praxis' drug reduces seizures but sees 23% discontinuation rate

Aug 4, 2025 10:22am
Cartoon of businessmen standing around a broken target

Spine BioPharma misses primary endpoint in back pain phase 3

Aug 1, 2025 10:24am
Closeup of blue eye on black background

4DMT climbs as gene therapy patients keep jettisoning jabs

Aug 1, 2025 5:35am